PART I Company Overview We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Pelareorep is a proprietary isolate of reovirus, a naturally ...
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001129928-26-000020 | EDGAR | 65K words |
No 10-Q filings indexed.
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-06 | 0001104659-26-039935 | EDGAR | 22K words |
| 2026-04-06 | 0001129928-26-000024 | EDGAR | — |
| 2026-04-01 | 0001104659-26-038272 | EDGAR | — |
| 2026-03-20 | 0001104659-26-032763 | EDGAR | — |
| 2026-03-19 | 0001129928-26-000011 | EDGAR | — |
| 2026-03-02 | 0001129928-26-000009 | EDGAR | — |
| 2026-02-24 | 0001129928-26-000006 | EDGAR | — |
| 2026-02-04 | 0001129928-26-000004 | EDGAR | — |
| 2026-01-15 | 0001104659-26-004103 | EDGAR | — |
| 2026-01-15 | 0001104659-26-003815 | EDGAR | — |
853 total filings indexed. 842 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001129928 |
| Ticker | ONCY |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.oncolyticsbiotech.com |
| Listed | 2001-10-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report